Literature DB >> 11272155

Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation.

J M Ye1, P J Doyle, M A Iglesias, D G Watson, G J Cooney, E W Kraegen.   

Abstract

Peroxisome proliferator-activated receptor (PPAR)-alpha agonists lower circulating lipids, but the consequences for muscle lipid metabolism and insulin sensitivity are not clear. We investigated whether PPAR-alpha activation improves insulin sensitivity in insulin-resistant rats and compared the effects with PPAR-gamma activation. Three-week high fat-fed male Wistar rats were untreated or treated with the specific PPAR-alpha agonist WY14643 or the PPAR-gamma agonist pioglitazone (both 3 mg x kg(-1) x day(-1)) for the last 2 weeks of high-fat feeding. Like pioglitazone, WY14643 lowered basal plasma levels of glucose, triglycerides (-16% vs. untreated), and leptin (-52%), and also muscle triglyceride (-34%) and total long-chain acyl-CoAs (LCACoAs) (-41%) (P < 0.05). In contrast to pioglitazone, WY14643 substantially reduced visceral fat weight and total liver triglyceride content (P < 0.01) without increasing body weight gain. WY14643 and pioglitazone similarly enhanced whole-body insulin sensitivity (clamp glucose infusion rate increased 35 and 37% and glucose disposal 22 and 15%, respectively, vs. untreated). Both agents enhanced insulin-mediated muscle glucose metabolic index (Rg') and reduced muscle triglyceride and LCACoA accumulation (P < 0.05). Although pioglitazone had more potent effects than WY14643 on muscle insulin sensitization, this was associated with its greater effect to reduce muscle LCACoA accumulation. Overall insulin-mediated muscle Rg' was inversely correlated with the content of LCACoAs (r = -0.74, P = 0.001) and with plasma triglyceride levels (r = -0.77, P < 0.001). We conclude that even though WY14643 and pioglitazone, representing PPAR-alpha and PPAR-gamma activation, respectively, may alter muscle lipid supply by different mechanisms, both significantly improve muscle insulin action in the high fat-fed rat model of insulin resistance, and this effect is proportional to the degree to which they reduce muscle lipid accumulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11272155     DOI: 10.2337/diabetes.50.2.411

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  78 in total

1.  Alpha-lipoic acid supplementation reduces mTORC1 signaling in skeletal muscle from high fat fed, obese Zucker rats.

Authors:  Zhuyun Li; Cory M Dungan; Bradley Carrier; Todd C Rideout; David L Williamson
Journal:  Lipids       Date:  2014-11-01       Impact factor: 1.880

2.  Essential nutrient supplementation prevents heritable metabolic disease in multigenerational intrauterine growth-restricted rats.

Authors:  Danielle Goodspeed; Maxim D Seferovic; William Holland; Robert A Mcknight; Scott A Summers; D Ware Branch; Robert H Lane; Kjersti M Aagaard
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

Review 3.  Peroxisome proliferator activated receptors, fatty acids and muscle insulin resistance.

Authors:  Edward Kraegen; Gregory Cooney; Ji-Ming Ye; Stuart Furler
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 4.  Ectopic fat accumulation: an important cause of insulin resistance in humans.

Authors:  Hannele Yki-Järvinen
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

5.  Early maternal undernutrition programs increased feed intake, altered glucose metabolism and insulin secretion, and liver function in aged female offspring.

Authors:  Lindsey A George; Liren Zhang; Nuermaimaiti Tuersunjiang; Yan Ma; Nathan M Long; Adam B Uthlaut; Derek T Smith; Peter W Nathanielsz; Stephen P Ford
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-01-25       Impact factor: 3.619

6.  Troxerutin suppresses lipid abnormalities in the heart of high-fat-high-fructose diet-fed mice.

Authors:  Rajagopalan Geetha; Baskaran Yogalakshmi; S Sreeja; K Bhavani; Carani Venkatraman Anuradha
Journal:  Mol Cell Biochem       Date:  2013-10-31       Impact factor: 3.396

7.  Intramyocellular lipids: maker vs. marker of insulin resistance.

Authors:  Zengkui Guo
Journal:  Med Hypotheses       Date:  2007-09-04       Impact factor: 1.538

8.  Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance.

Authors:  Cheol Soo Choi; Jonathan J Fillmore; Jason K Kim; Zhen-Xiang Liu; Sheene Kim; Emily F Collier; Ameya Kulkarni; Alberto Distefano; Yu-Jin Hwang; Mario Kahn; Yan Chen; Chunli Yu; Irene K Moore; Richard M Reznick; Takamasa Higashimori; Gerald I Shulman
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

9.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 10.  Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  BMC Gastroenterol       Date:  2010-05-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.